[AUO study in hormone-refractory prostate cancer. Phase III study on treatment of hormone-refractory prostate cancer (HRPC) with docetaxel: continuous treatment vs. intermittent repetition of treatment after renewed progression--PRINCE].
Rexer
H
H
Geschäftsstelle der AUO, MeckEvidence, Seestrasse 11, 17252 Schwarz. AUO@MeckEvidence.de
D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D000077143:Docetaxel; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage*
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel